China Resources (Guangdong) Medical Laboratory and Pingsheng Medical Announce Strategic Partnership to Advance Clinical Mass Spectrometry Solutions
January 9, 2024CR Pharma Member Enterprise CR (Guangdong) Medical Laboratory Co., Ltd. Announces Strategic Partnership with Pingsheng Medical, a Leader in Clinical Mass Spectrometry and Multi-Omics, both parties will fully leverage their respective strengths, seize the development opportunities in clinical mass spectrometry and multi-omics, provide one-stop, comprehensive mass spectrometry solutions to end-user medical institutions, better promote innovative development in the industry, and serveNational economy and people's livelihood. Du Chunwei, General Manager of China Resources (Guangdong) Medical Laboratory Co., Ltd., Cheng Xiaoliang, President, Chairman, and CEO of Pinsheng Medical Group, and others attended the signing ceremony.
Du Chunwei (right), General Manager of China Resources (Guangdong) Medical Laboratory Co., Ltd., and Liu Wenting (left), Senior Vice President of Pinsheng Medical, sign a strategic cooperation agreement
As one of the most advanced detection technologies available today, mass spectrometry serves as a critical technological platform for achieving precision medicine and is rapidly developing and gaining widespread adoption in clinical diagnosis and treatment. The application of mass spectrometry not only provides more precise diagnostic tools for clinical laboratory testing, thereby assisting clinicians in formulating more accurate diagnostic and therapeutic strategies; furthermore, multi-omics technologies centered on mass spectrometry have provided substantial momentum for clinical research. Particularly in the study of pathogenic mechanisms and the discovery of biomarkers and therapeutic targets, multi-omics technologies have assumed an increasingly vital role, robustly supporting continuous innovation in clinical research.
In recent years, policy support for the development of clinical mass spectrometry has been intensified. The 14th Five-Year Plan for Bioeconomy Development explicitly proposes to "carry out frontier biotechnological innovation." The National Health Commission has also issued guiding opinions on promoting the capacity building of clinical specialties, stating that by the end of 2025, the foundational capabilities of basic and platform specialties will be further strengthened, innovative breakthroughs will be achieved in disease-specific diagnosis and treatment models and disciplinary organizational forms for major diseases with high incidence rates and severe impacts on public health, and a batch of specialized clinical departments will be established to provide patients with one-stop, full-process diagnostic and therapeutic services.
With the advancement of precision medicine, local governments are actively promoting the establishment of precision medicine centers to implement the “Healthy China” initiative. To better leverage mass spectrometry technology—characterized by high sensitivity, high specificity, and high accuracy—for clinical applications, multiple regional medical laboratory centers are striving to build dedicated mass spectrometry centers. These efforts aim to complement the limitations of traditional methods with more precise test results, thereby maximizing the role of laboratory medicine in clinical practice.
China Resources (Guangdong) Medical Laboratory Co., Ltd. is a subsidiary of China Resources Pharmaceutical Commercial Group Medical Devices (hereinafter referred to as “CR Medical Devices”) Co., Ltd., deeply engaged in medical laboratory-related services in the South China region.Business.Leveraging the strong brand strength of China Resources Pharmaceutical Group and the leading market coverage capabilities of China Resources Medical Devices, China Resources (Guangdong) Medical Laboratory Co., Ltd. enjoys extensive influence and deep channel resources in the region.PinshengPingsheng Medical is a pioneer in the field of clinical mass spectrometry and multi-omics technology in China, with comprehensive layouts in multi-omics research, innovative diagnostic applications, integrated clinical mass spectrometry solutions, and patent barriers. In recent years, Pingsheng Medical has continuously upgraded its marketing system, actively empowered ecosystem partners, and built a healthy development ecosystem for China's clinical mass spectrometry industry.
In this collaboration, China Resources (Guangdong) Medical Laboratory Co., Ltd. will work with Pingsheng Medical to implement comprehensive clinical mass spectrometry solutions across key regions including South China, Central China, East China, and Southwest China. This initiative aims to support the development of precision medicine centers nationwide, establish regional mass spectrometry ecosystems, and thereby elevate the overall level of precise diagnosis and treatment in these areas.
Du Chunwei, General Manager of China Resources (Guangdong) Medical Laboratory Co., Ltd.
Signing Ceremonyabove,HuaDu Chunwei, General Manager of Run (Guangdong) Medical Laboratory Co., Ltd.stated: “In recent years, with theWith the rapid development of mass spectrometry technology in the field of clinical laboratory testing, it has received extensive attention from the industry. We are delighted to have entered into a strategic partnership with Pingsheng Medical, an outstanding enterprise in clinical mass spectrometry, and we are confident about this collaboration. We look forward to jointly promoting technological innovation in the laboratory testing industry and fostering the healthy and sustainable development of regional healthcare through our combined efforts.”
Cheng Xiaoliang, Chairman of Pinsheng Medical
Cheng Xiaoliang, President, Chairman, and CEO of Pinsheng Medical Groupstated: “China Resources (Guangdong) Medical Laboratory Co., Ltd. possesses strong brand and business network advantages, while Pingsheng Medical ranks among the industry’s first tier in capabilities related to the development of integrated clinical mass spectrometry solutions, independent innovation in mass spectrometry equipment, and multi-omics research. With a solid foundation for cooperation and shared visionary goals, both parties anticipate that this strategic partnership will deliver more valuable integrated clinical mass spectrometry solutions in support of the Healthy China Initiative, vigorously promote the application of mass spectrometry technology in the field of precision diagnosis and treatment, and enable broader public access to its benefits.”
Talk Venue
Group Photo of Representatives from China Resources (Guangdong) Medical Laboratory Co., Ltd. and Pingsheng Medical
Ge Shaoyun, Deputy General Manager of China Resources (Guangdong) Medical Laboratory Co., Ltd.; Diao Juncheng, Director; Che Zhan, Director; Wang Rong, Chief Scientist of Pingsheng Medical Group; Liu Wenting, Senior Vice President; and Yang Min, Vice President, attended the strategic cooperation signing ceremony.